Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Bioscience (RCUS) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies targeting cancer’s immunosuppressive mechanisms. This page provides investors and researchers with timely updates on the company’s developments in immuno-oncology, including advancements in its ATP-adenosine pathway research.
Access the latest press releases, clinical trial milestones, and financial disclosures in one centralized hub. Track updates on therapeutic candidates spanning small molecules and biologics, partnership announcements, and regulatory progress. Our curated news collection ensures you stay informed about RCUS’s efforts to address unmet needs in lung, colorectal, and pancreatic cancers.
Bookmark this page for real-time insights into Arcus Bioscience’s R&D pipeline, strategic initiatives, and industry positioning. Check back regularly for verified updates directly from corporate communications and trusted financial sources.
Gilead Sciences and Arcus Biosciences announced promising results from the Phase 2 EDGE-Gastric study evaluating domvanalimab plus zimberelimab and chemotherapy in treating upper gastrointestinal (GI) cancers. The updated data show a median progression-free survival (PFS) beyond one year, surpassing historical benchmarks for similar treatments. Nearly 60% of patients achieved 12-month PFS. The ongoing Phase 3 STAR-221 study aims to further validate these results. The combination therapy was well-tolerated with a safety profile consistent with the individual components. These outcomes support the potential for this combination to address unmet needs in upper GI cancer treatment.
Arcus Biosciences announced that its Compensation Committee granted three new employees options to purchase a total of 16,300 shares of the company's common stock at an exercise price of $16.28 per share. The closing price on May 23, 2024, determined this amount.
Additionally, the company awarded restricted stock units to acquire a total of 8,150 shares. These equity awards align with the company's 2020 Inducement Plan, approved by the Board of Directors in January 2020 under the “inducement exception” provided by NYSE Rule 303A.08.
Arcus Biosciences, Inc. announced the grant of employment inducement options and restricted stock units to new employees. The total grant includes 141,100 shares of common stock options and 70,555 restricted stock units. The awards were issued under the Company's 2020 Inducement Plan, approved by the Board of Directors in January 2020.
Arcus Biosciences, Inc. (NYSE:RCUS) reported financial results for Q1 2024 and provided a pipeline update focusing on TIGIT, adenosine axis, HIF-2a, AXL, and PD-1 molecules targeting lung, gastrointestinal, and kidney cancers. Key updates include data presentations at ASCO, Phase 3 studies enrollment, and expansion cohorts for casdatifan in ccRCC. With $1.1 billion in cash, Arcus is well-positioned for pipeline advancement. Financially, Q1 2024 saw increased revenues, R&D expenses, and cash reserves to fund operations into 2027.
Arcus Biosciences (NYSE:RCUS) will participate in a fireside chat at the Bank of America Healthcare Conference 2024. The company focuses on developing cancer treatments and will have a live webcast on May 16th, 2024.
FAQ
What is the current stock price of Arcus Bioscience (RCUS)?
What is the market cap of Arcus Bioscience (RCUS)?
